Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prevalence and Pathogenesis of Barrett's Esophagus in Luoyang, China

  • Zhang, Ru-Gang (Department of Gastroenterology and Hepatology, Chinese PLA General Hospital) ;
  • Wang, Chang-Song (Department of Pathology, Southwest Hospital, 150th Hospital of Chinese PLA) ;
  • Gao, Cun-Fang (Department of Gastroenterology and Hepatology, Southwest Hospital, 150th Hospital of Chinese PLA)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Prevalence of Barrett's esophagus (BE) in Luoyang, China, has not been reported, and its pathogenesis is controversial. The aim of this study was therefore to investigate the prevalence of BE and its underlying factors in the city of Luoyang. Method: This was a prospective study in one center. Many patients were analyzed using endoscopy who showed upper gastrointestinal symptoms between August 2006 and June 2007. In addition, the effect of apoptosis-related proteins and heat shock proteins upon BE's pathogenesis were also investigated by an immunohistochemical protocol. Results: Prevalence of BE was at 4.55% and the mean age of those affected was about 10 years older than for esophagitis. Typical reflux symptoms were significantly lower than with esophagitis, whereas signs of caspase-3 and HSP105 elevation were significantly higher. Expression of TERT, HSP70 and $HSP90{\alpha}$ in BE cases was significantly lower than in esophagitis. However, there was no statistical difference between the two groups in expression of HSP27. Conclusions: The prevalence of BE is high in Luoyang, which could result from esophagitis despite typical reflux symptoms being relatively uncommon. Initiation and development of BE might be the result of accelerated proliferation, apoptosis and differentiation of original cells to intestinal epithelium.

Keywords

References

  1. Aldulaimi DM, Cox M, Nwokolo CU, Loft DE (2005). Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol, Sep, 17, 943-50. https://doi.org/10.1097/00042737-200509000-00010
  2. Al Madi MA (2009). Barrett's esophagus: where do we stand? Saudi J Gastroenterol, 15, 2-10. https://doi.org/10.4103/1319-3767.45046
  3. Burnat G, Majka J, Konturek PC (2010). Bile acids are multifunctional modulators of the Barrett's carcinogenesis. J Physiol Pharmacol, 61, 185-92.
  4. Cande C, Cohen I, Daugas E et al (2002). Apoptosis-inducing factor(AIF): a novel caspase independent death effector released from mitochondria. Biochimie, 84, 215-22. https://doi.org/10.1016/S0300-9084(02)01374-3
  5. Casson AG, Williams L, Guernsey DL (2005). Epidemiology and molecular biology of Barrett esophagus. Semin Thorac Cardiovasc Surg, 17, 284-291. https://doi.org/10.1053/j.semtcvs.2005.09.005
  6. Chen Xue-mei, ZOU Fei (2006). Stress response changes of NIH-3T3 cells with HSP90$\alpha$ expression inhibition by RNA interference. J South Med Univ, 26, 1118-20.
  7. Ciriza-de-los-Rios C. Barrett s esophagus - a review. Rev Esp Enferm Dig, 102, 257-69.
  8. Clement G, Braunschweig R, Pasquier N et al (2006). Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation. J Pathol, 208, 100-7. https://doi.org/10.1002/path.1884
  9. Didelot C, Schmitt E, Brunet M et al (2006). Heat shock proteins: endogenous modulators of apoptotic cell death. Handb Exp Pharmacol, 171-98.
  10. Doak SH, Jenkins GJ, Parry EM (2004). Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression. Mutat Res, 547, 133-44. https://doi.org/10.1016/j.mrfmmm.2003.12.009
  11. Dzaman-Serafin S, Telatynska-Mieszek B, Ciechanowski K (2005). Heat shock proteins and their characteristics. Pol Merkur Lekarski, 19, 215-9.
  12. Fouad YM, Makhlouf MM, Tawfik HM(2009). Barrett's esophagus: prevalence and risk factors in patients with chronic GERD in Upper Egypt. World J Gastroenterol, 15, 3511-15. https://doi.org/10.3748/wjg.15.3511
  13. Gertler R, Doll D, Maak M, Feith M, Rosenberg R (2008). Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer, 112, 2173-80. https://doi.org/10.1002/cncr.23419
  14. Glickman JN, Chen YY, Wang HH, Antonioli DA, Odze RD (2001). Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am J Surg Pathol, 25, 569-78. https://doi.org/10.1097/00000478-200105000-00002
  15. Ishihara K, Yamagishi N, Saito Y et al (2003). Hsp105 alpha suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity. J Biol Chem, 278, 25143-50. https://doi.org/10.1074/jbc.M302975200
  16. Jones TF, Sharma P, Daaboul B (2002). Yield of intestinal metaplasia in patients with suspected short-segment Barrett's esophagus (SSBE) on repeat endoscopy. Dig Dis Sci, 47, 2108-11. https://doi.org/10.1023/A:1019697501650
  17. Kim JH, Rhee PL, Lee JH (2007). Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol, 22, 908-12. https://doi.org/10.1111/j.1440-1746.2006.04448.x
  18. Lavrik IN, Golks A, Krammer PH (2002). Caspases: pharmacological manipulation of cell death. J Clin Invest, 115, 2665-72.
  19. Maser RS, DePinho RA (2002). Connecting chromosomes, crisis, and cancer. Science, 297, 565-9. https://doi.org/10.1126/science.297.5581.565
  20. Modiano N, Gerson LB (2007). Barrett's esophagus: Incidence, etiology, pathophysiology, prevention and treatment. Ther Clin Risk Manag, 3, 1035-145.
  21. Neckers L (2007). Heat shock protein 90: the cancer chaperone. J Biosci, 32, 517-30. https://doi.org/10.1007/s12038-007-0051-y
  22. Ostrowski J, Mikula M, Karczmarski J (2007). Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med, 85, 733-43. https://doi.org/10.1007/s00109-007-0176-3
  23. Pandey P, Saleh A, Nakazawa A (2000). Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J, 19, 4310-22. https://doi.org/10.1093/emboj/19.16.4310
  24. Parenti A, Leo G, Porzionato A (2006). Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis. Hum Pathol, 37, 16-22. https://doi.org/10.1016/j.humpath.2005.10.003
  25. Paull A, Trier JS, Dalton MD (1976). The histologic spectrum of Barrett's esophagus. N Engl J Med, 295, 476-80. https://doi.org/10.1056/NEJM197608262950904
  26. Sarosi G, Brown G, Jaiswal K (2008). Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus, 21, 43-50. https://doi.org/10.1111/j.1442-2050.2007.00744.x
  27. Sawhney RA, Shields HM, Allan CH (1996). Morphological characterization of the squamocolumnar junction of the esophagus in patients with and without Barrett's epithelium. Dig Dis Sci, 41, 1088-98. https://doi.org/10.1007/BF02088224
  28. Sharma P, Dent J, Armstrong D (2006). The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology, 131, 1392-9. https://doi.org/10.1053/j.gastro.2006.08.032
  29. Smith CM, Watson DI, Michael MZ, Hussey DJ (2010). MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol, 16, 531-7. https://doi.org/10.3748/wjg.v16.i5.531
  30. Soldes OS, Kuick RD, Thompson IA 2nd, et al (1999). Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br J Cancer, 79, 595-603. https://doi.org/10.1038/sj.bjc.6690094
  31. Sollano JD, Wong SN, Andal-Gamutan T (2007). Erosive esophagitis in the Philippines: a comparison between two time periods. J Gastroenterol Hepatol, 22, 1650-5. https://doi.org/10.1111/j.1440-1746.2006.04355.x
  32. Souza RF. Biomarkers in Barrett's Esophagus (2010). Tech Gastrointest Endosc, 12, 116-1212. https://doi.org/10.1016/j.tgie.2010.02.006
  33. van Kerkhoven LA, van Rijswijck SJ, van Rossum LG (2007). Open-access upper gastrointestinal endoscopy a decade after the introduction of proton pump inhibitors and helicobacter pylori eradication: a shift in endoscopic findings. Digestion, 75, 227-31. https://doi.org/10.1159/000110684
  34. Wang KK, Sampliner RE (2008). Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol, 103, 788-97. https://doi.org/10.1111/j.1572-0241.2008.01835.x
  35. Wang W, Zhang ZJ, Lin KR, et al (2006). The prevalence, clinical and endoscopic characteristics of Barrett esophagus in Fujian. Chin J Intern Med, 45, 393-5 (in Chinese).
  36. Zhang J, Zhang S, Luo J, et al (2001). Barrett' s esophagus: clinical study. Chin J Dig Endosc, 18, 15-8 (in Chinese).

Cited by

  1. Effects of Mechanical Stretching on the Morphology and Cytoskeleton of Vaginal Fibroblasts from Women with Pelvic Organ Prolapse vol.16, pp.12, 2015, https://doi.org/10.3390/ijms16059406